REG - Medpal AI PLC - Result of WRAP Retail Offer

Medpal AIAnnouncement

Yesterday 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260325:nRSY0879Ya&default-theme=true

RNS Number : 0879Y  Medpal AI PLC  25 March 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND,
CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER
JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE
A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF
ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK
MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

 

25 March 2026

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

Result of WRAP Retail Offer

 

Further to its announcement of 20 March 2026, MedPal AI plc (AIM: MPAL,
FRA:Z1N), the UK digital health and AI company, is pleased to confirm the
result of its WRAP Retail Offer ("WRAP"). The WRAP Retail Offer has raised
gross proceeds of approximately £105,160. In addition the Company has entered
into a subscription agreement to raise a further £300,000 at 2.5p per share
(the "Subscription"). With the proceeds of the Placing of £527,000 announced
on 20 March 2026, in aggregate the Company has therefore raised gross proceeds
of approximately £932,160 at a price of 2.5 pence per new ordinary share. The
Company will issue 16,206,396 new Ordinary Shares ("Fundraise Shares") in
respect of the WRAP and the Subscription.

 

Admission and Total Voting Rights

Application has been made for the Fundraise Shares to be admitted to trading
on AIM along with the Placing Shares ("Admission"). Admission is expected to
become effective and dealings in the shares are expected to commence on or
around 26 March 2026.

 

Upon Admission, the Company's issued ordinary share capital will consist of
492,441,036 Ordinary Shares with one voting right each. The Company does not
hold any Ordinary Shares in treasury. Therefore, from Admission the total
number of Ordinary Shares and voting rights in the Company will be
492,441,036. With effect from Admission, this figure may be used by
Shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

The new Ordinary Shares to be issued pursuant to the Placing, Subscription and
WRAP Retail Offer will be issued free of all liens, charges and encumbrances
and will, on Admission, rank pari passu in all respects with the Company's
existing Ordinary Shares.

 

Capitalised terms used but not defined in this announcement have the same
meaning as set out in the Company's announcement released on 20 March 2026.

For further information, please contact:

 MedPal AI plc                       www.medpalplc.com (https://www.medpalplc.com/)

 Jason Drummond

 Cairn Financial Advisers LLP        +44(0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited       +44(0) 20 3869 6080

 Bob Roberts

 Winterflood Retail Access Platform  WRAP@winterflood.com

 Sophia Bechev, Kaitlan Billings     +44(0) 20 3100 0214

Further information on the Company can be found on its website at
www.medpalplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIUVSKRNBUOURR



            Copyright 2019 Regulatory News Service, all rights reserved